Akums Drugs and Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 08, 2025, titled "Press Release".
AKUMS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Akums Drugs and Pharmaceuticals reported Q1 FY26 consolidated total income of ₹1,051 crore, with adjusted EBITDA of ₹156 crore, a strong 19.1% year-on-year growth. EBITDA margins expanded by 208 basis points to 14.8% from 12.7% last year, while adjusted PAT stood at ₹65 crore (margin 6.2%, up from 5.6%). The company crossed a key milestone of 1,000 Drug Controller General of India (DCGI) approvals, adding 27 fresh approvals this quarter. It also secured its first European dossier approval for Rivaroxaban and filed a Dapagliflozin combination dossier in Switzerland, with European commercial supplies slated from April 2027. Akums received €100 million as part consideration for its European contract, boosting its cash surplus to ₹1,518 crore. The CDMO segment contributed ~79% of group turnover with 14.7% segment EBITDA, while trade generics and API remained in operational loss.
Positive for shareholders — strong profit growth, margin expansion, a cash-rich balance sheet, and progress on global CDMO expansion signal healthy fundamentals, though continued losses in the trade generics and API segments remain a watch point.